C8981

Carbamazepine

Name: Carbamazepine
Brand: SIAL

meets USP testing specifications

Sinónimos:

5H-Dibenz[b,f]azepine-5-carboxamide

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Todas las fotos(2)

About This Item

Fórmula empírica (notación de Hill):

C₁₅H₁₂N₂O

Número CAS:

298-46-4

Peso molecular:

236.27

NACRES:

NA.21

PubChem Substance ID:

24893120

UNSPSC Code:

41116107

EC Number:

206-062-7

MDL number:

MFCD00005073

Nombre del producto

Carbamazepine, meets USP testing specifications

InChI key

FFGPTBGBLSHEPO-UHFFFAOYSA-N

InChI

1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)

SMILES string

NC(=O)N1c2ccccc2C=Cc3ccccc13

agency

USP/NF
meets USP testing specifications

form

solid

mp

191-192 °C (lit.)

storage temp.

2-8°C

Quality Level

200

Gene Information

human ... PRNP(5621), SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335)
rat ... Scn2a1(24766), Scnn1a(25122), Scnn1g(24768), Slc6a1(79212)

¿Está buscando productos similares? Visita Guía de comparación de productos

Biochem/physiol Actions

Anticonvulsant; ligand for the GABA_A receptor benzodiazepine modulatory site. Sodium channel inhibitor.

pictograms

GHS08,GHS07

signalword

Danger

hcodes

H302,H317,H334,H336,H360FD

pcodes

P202 - P261 - P280 - P301 + P312 - P302 + P352 - P308 + P313

Hazard Classifications

Acute Tox. 4 Oral - Repr. 1A - Resp. Sens. 1 - Skin Sens. 1A - STOT SE 3

target_organs

Central nervous system

Clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 2

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.

U Amstutz et al.

Clinical pharmacology and therapeutics, 94(1), 142-149 (2013-04-17)

The occurrence of hypersensitivity reactions including rare but life-threatening Stevens-Johnson syndrome (SJS) and drug-induced hypersensitivity syndrome (HSS) limits the use of the anticonvulsant carbamazepine (CBZ). Human leukocyte antigen-B (HLA)-B 15:02 and HLA-A 31:01 have been identified as predictive genetic markers

Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study.

Janneke Jentink et al.

BMJ (Clinical research ed.), 341, c6581-c6581 (2010-12-04)

To identify specific major congenital malformations associated with use of carbamazepine in the first trimester of pregnancy. A review of all published cohort studies to identify key indications and a population based case-control study to test these indications. Review of

Network-specific mechanisms may explain the paradoxical effects of carbamazepine and phenytoin.

Evan A Thomas et al.

Epilepsia, 54(7), 1195-1202 (2013-04-10)

A common notion of the mechanism by which the antiepileptic drugs (AEDs) carbamazepine and phenytoin act is that they block sodium channels by binding preferentially to the inactivated state, thereby allowing normal neuronal firing while blocking ictal activity. However, these

Antiseizure activity of novel gamma-aminobutyric acid (A) receptor subtype-selective benzodiazepine analogues in mice and rat models.

Felix M Rivas et al.

Journal of medicinal chemistry, 52(7), 1795-1798 (2009-03-12)

The antiseizure activity of benzodiazepines (BDZs) 1-5 in mice and rats as animal models is described. These BDZs have selective efficacy for alpha2beta3gamma2 and alpha3beta3gamma2 GABA(A)-receptors. Significant anticonvulsant activity with little or no motor impairment and therapeutic indexes (TI) of

Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.

Ursula Amstutz et al.

Epilepsia, 55(4), 496-506 (2014-03-07)

To systematically review evidence on genetic risk factors for carbamazepine (CBZ)-induced hypersensitivity reactions (HSRs) and provide practice recommendations addressing the key questions: (1) Should genetic testing for HLA-B*15:02 and HLA-A*31:01 be performed in patients with an indication for CBZ therapy

Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico